✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Morgan Stanley’s Vintage Values 2027: 10 Stocks Analysts See Climbing Further

Page 1 of 3

According to a November 13 Bloomberg report, strategists at a major Wall Street bank expect the S&P 500 to reach 8,700 within 12 months. They also see earnings growth slowing to 11% in 2027 from 36% in 2026. That gap matters because slower profit growth changes what investors reward. According to the report, buyers are willing to pay up for companies that keep growing, because growth is becoming harder to find. For stock pickers, that raises the value of any name where earnings momentum is still intact. It matters most when the market has not yet priced all of it in.

Slower Profit Growth Raises the Bar

On November 13, chip stocks sold off and the S&P 500 fell 0.4%, although it still gained about 2.5% on the week, according to Yahoo Finance’s market coverage. Wholesale inflation also reached its highest annual rate in nearly four years, and the 10-year Treasury yield closed at 5.15% on November 13. Higher yields make future earnings worth less today. That is one reason the largest technology companies have drawn scrutiny, since their spending has pushed free cash flow negative. Even so, Bloomberg’s report described them as “relatively defensive.” Readers who want a broader look at the rebound case can see our ranking of oversold AI stocks where Wall Street analysts see big upside.

What a Price Target Really Means

A price target is an analyst’s estimate of where a stock should trade in about 12 months, built from forecasts for earnings, growth, and a reasonable valuation multiple. Upside is simply the gap between today’s share price and the average of those targets, expressed as a percentage. Because targets are opinions rather than guarantees, they can move quickly after a company reports, and a cut does not always mean the analyst has turned negative. Sometimes a firm trims its target to reflect a stock that has already risen, or an expectations bar that was set too high, while keeping a positive rating.

That is why the rating and the target are best read together. An upgrade with a lower target tells a different story from a reiterated rating with a higher one. The reasons behind a change, such as delayed contracts, better cost control or a pricing shift, usually say more than the number does. Ranking by average upside adds a second layer. A large gap to the average target can point to a stock that has fallen out of favor as easily as to one analysts expect to take off. Our list of NYSE-listed stocks with large analyst-estimated upside shows how wide that spread can get on a single exchange. Following the reasons as well as the numbers keeps that distinction clear.

Our Methodology

To compile this list, we looked at the 15 US-listed stocks in Morgan Stanley’s Vintage Values 2027 portfolio and ranked them by average upside potential, based on analysts’ average price target. We then picked the 10 with the highest upside that had a full year of share price history and a positive share price performance over that period, and counted the list down from there. We also list each stock’s market cap and its share price performance over the past year.

Note: All data was sourced on November 16, 2026.

At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

Morgan Stanley’s Vintage Values 2027: 10 Stocks Analysts See Climbing Further

10. Eli Lilly (NYSE:LLY)

Market Cap: $1.37 trillion

Average Upside Potential: 4%

1-Year Performance: 41.66%

Jefferies raised its price target on Eli Lilly to $1,700 from $1,610 on November 9, 2026, the highest target on Wall Street. The firm argued that the international obesity market could be at least as large as the U.S. market, with about twice as many potential patients. It also said realized prices could rise as patients move to higher doses. Eli Lilly is a drugmaker whose diabetes and weight-loss medicines, Mounjaro and Zepbound, drive most of its growth.

Not every firm agrees. China Merchants Securities downgraded the stock to Hold from Buy on November 12, 2026.

The company reported results for the third quarter of 2026 on October 29, 2026. Revenue rose 39% to $24.4 billion on higher volume, though lower realized prices held back growth. Management credited broad global demand for Mounjaro and Zepbound and the launches of Foundayo, its oral obesity drug. Lilly raised its full-year revenue guidance, and Chief Executive Officer Dave Ricks said the third quarter exceeded the company’s prior expectations. Positive head-to-head results for retatrutide against Ozempic in type 2 diabetes added to the pipeline case. We covered whether Lilly’s growth can keep justifying its premium valuation in a separate piece.

9. McKesson (NYSE:MCK)

Market Cap: $128.62 billion

Average Upside Potential: 4%

1-Year Performance: 32.29%

UBS analyst Kevin Caliendo raised his price target on McKesson to $1,250 from $1,200 on November 5, 2026, and kept a Buy rating. McKesson is a healthcare distributor that supplies medicines and medical products to pharmacies, health systems and care providers.

The note followed results for the second quarter of fiscal 2027, ended September 30, 2026, which the company released on November 4, 2026. Revenue increased 8% to $111.0 billion, and adjusted earnings per share rose 18% to $11.68. McKesson also raised its full-year adjusted earnings per share guidance, and its oncology and multispecialty business grew faster than any other segment.

On October 5, 2026, the company agreed to take a minority stake in Option Care Health, a home and alternate-site infusion provider. On November 2, 2026, it completed the acquisition of Precision Medicine Group, a clinical research and biopharma commercialization firm. Executives said the Precision Medicine Group deal strengthens McKesson’s oncology and biopharma services platforms. Chief Executive Officer Brian Tyler described the Option Care Health investment as a way into home and community-based care, with Clayton, Dubilier & Rice holding the majority stake. Our take on whether the Option Care Health deal is justified covers the price paid.

Page 1 of 3